Inclusion Criteria:
- Pathologic diagnosis of pancreatic carcinoma
- Radiologic evidence of hepatic metastasis with at least one lesion > 2.0 cm that is
amenable to ultrasound or CT guided intra-tumoral DC injection
- Age > 18
- Life expectancy > 3 months
- Karnofsky Performance Status > 70%
- Patients must not have received any anti-neoplastic chemotherapy, immunotherapy or
radiotherapy for the four weeks preceding entry onto the study (six weeks for
nitrosoureas and mitomycin C).
- Adequate baseline hematopoietic function defined as WBC > 3000/mm3, hemoglobin >
9g/dl, and platelet count > 100,000/mm3.
- Adequate baseline organ function defined as creatinine < 2.0, total bilirubin < 2.0
mg/dl
- Patients taking warfarin are not eligible. Adequate coagulation function defined as
PT < 15, INR < 1.5 and PTT < 35.
- Ability to give informed consent
Exclusion Criteria:
- Previous anti-tumor vaccine therapy
- Prior hepatic irradiation
- Known brain metastases
- History of prior autoimmune diseases (e.g. SLE, rheumatoid arthritis, myasthenia
gravis)
- Regular corticosteroid use within the past one year or any corticosteroid use in the
four weeks preceding study entry
- Evidence of HIV infection, AIDS, Hepatitis B or Hepatitis C infection
- Active bacterial, fungal or viral infection
- Pregnancy or lactation; women of childbearing potential and men must agree to use
effective contraception during the course of this clinical trial
- Uncontrolled or unstable medical conditions including angina, arrhythmias, bleeding,
or thromboembolic conditions,
- Any medical or psychiatric illness that might compromise the patients ability to
tolerate treatment